Bavachinin

Bavachinin (7-O-Methylbavachin) is a novel natural pan-PPAR agonist from the fruit of the traditional Chinese glucose-lowering herb malaytea scurfpea. It shows stronger activities with PPAR-γ than with PPAR-α and PPAR-β/δ (EC50 = 0.74 μmol/l, 4.00 μmol/l and 8.07 μmol/l in 293T cells, respectively).

CAS No. 19879-30-2

サイズ	価格(税別)	在庫状況
10mg	JPY 18800	国内在庫あり
25mg	JPY 31800	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

製品安全説明書

現在のバッチを見る： S387801 DMSO] 67 mg/mL] false] ] ] false] ] ] false 純度： 99.99%

99.99

Bavachinin関連製品

関連ターゲット	PPARα PPARβ/δ PPARγ PPARδ	もっと見る
関連製品	T0070907 Rosiglitazone GW9662 Pioglitazone Rosiglitazone maleate Rosiglitazone HCl GW6471 WY-14643 (Pirinixic Acid) Fenofibrate GSK3787 GW0742 AZ6102 Astaxanthin Eupatilin Troglitazone GSK0660 Oroxin A Bezafibrate Fenofibric acid Harmine Palmitoylethanolamide Lanifibranor (IVA-337) DG172 dihydrochloride Glabridin Ciprofibrate Clofibric Acid Alpinetin Elafibranor Daidzein Gypenoside XLIX	もっと見る
関連化合物ライブラリー	Metabolism Compound Library Anti-cancer Metabolism Compound Library Glutamine Metabolism Compound Library Carbohydrate Metabolism Compound Library Lipid Metabolism Compound Library	もっと見る

シグナル伝達経路

PPARシグナル伝達経路

PPAR阻害剤の選択性比較

生物活性

製品説明

Bavachinin (7-O-Methylbavachin) is a novel natural pan-PPAR agonist from the fruit of the traditional Chinese glucose-lowering herb malaytea scurfpea. It shows stronger activities with PPAR-γ than with PPAR-α and PPAR-β/δ (EC50 = 0.74 μmol/l, 4.00 μmol/l and 8.07 μmol/l in 293T cells, respectively).

Targets

PPARγ ^[1] (Cell-free assay)	PPAR-β/δ ^[1] (Cell-free assay)	PPARα ^[1] (Cell-free assay)
223 nM(Ki)	5.275 μM(Ki)	7.881 μM(Ki)

In Vitro
In vitro	Bavachinin inhibits increases in HIF-1α activity in human KB carcinoma (HeLa cellderivative)and human HOS osteosarcoma cells under hypoxia in a concentration-dependent manner, probably by enhancing the interaction between von Hippel-Lindau (VHL) and HIF-1α. Furthermore, Bavachinin decreases transcription of genes associated with angiogenesis and energy metabolism that are regulated by HIF-1, such as vascular endothelial growth factors (VEGF), Glut1 and Hexokinase2. Bavachinin also inhibits tube formation in human umbilical vein endothelial cells (HUVECs) as well as in vitro migration of KB cells. Bavachinin inhibits nitricoxide production in macrophages activated by lipopolysaccharide^[2].
細胞実験	細胞株	HOS and KB Cells
	濃度	--
	反応時間	24 h
	実験の流れ	HOS and KB Cells(1×10⁴) are seeded onto a 96-well plate with medium supplemented with 10% FBS and incubated for 24 h. Cells are then exposed to various concentrations of Bavachinin for an additional 24 h in hypoxic conditions. Cells are washed twice with phosphate-buffered saline and cell survival is assayed by treating with 100 μg/ml of MTT for 2h at 37 ℃. After washing with phosphate buffered saline, the resulting purple formazan is dissolved in 200 ml of dimethylsulphoxide and its absorbance is read at 540 nm.

In Vivo
In Vivo	In db/db and DIO mice, BVC treatment ameliorates diabetes, hyperlipidaemia and BVC improves hepatotoxicity. BVC enhances glucose transport and utilisation, hepatic lipid turnover and fatty acid metabolism through PPAR networks, thereby improving insulin sensitivity, dyslipidaemia and fatty liver^[1]. In vivo studies show that injecting Bavachinin thrice weekly for four weeks significantly reduces tumor volume and CD31 expression in nude mice with KB xenografts^[2]. Following IV administration of bavachinin at 25 mg/kg to naïve female BALB/c mice, clearance is high (mean CL = 299.72 mL/min/kg) and is approximately 3.33-fold of hepatic blood flow. The mean volume of distribution of bavachinin is 11881.67 mL/kg, it is 16.39 times of total body water volume (725 mL/kg), indicating high extravascular distribution. The mean terminal half-life following IV dosing is 0.70 h, this is reflected a tight correlation between the clearance and terminal half-life. The PK properties of bavachinin are characterized as rapid oral absorption, high clearance, and poor absolute bioavailability following single oral and intravenous administration to naïve female BALB/c mice^[3].
動物実験	動物モデル	Female athymic nude mice
	投与量	5 mg/kg
	投与経路	i.p.

参考
[1] Feng L, et al. Diabetologia. 2016, 59(6):1276-86. [2] Nepal M, et al. Eur J Pharmacol. 2012, 691(1-3):28-37. [3] Liu L, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2012, 893-894:21-8.

参考

化学情報

分子量	338.40	化学式	C₂₁H₂₂O₄
CAS No.	19879-30-2	SDF	Download Bavachinin SDFをダウンロードする
Smiles	CC(=CCC1=CC2=C(C=C1OC)OC(CC2=O)C3=CC=C(C=C3)O)C
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 67 mg/mL ( (197.99 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):